Swedish Orphan extends Ruconest agreement and places more orders with Pharming
This article was originally published in Scrip
Executive Summary
Swedish Orphan Biovitrium (SOBI) has extended its current commercialisation agreement with Pharming for Ruconest (recombinant human C1 inhibitor), a treatment for acute angiooedema attacks in patients with Hereditary Angioedema (HAO), to include the additional territories of the Balkans, North Africa and the Middle East.